1. Home
  2. Analysis
  3. Naphcon-a
  4. Lantus-solostar

Naphcon-a and Lantus solostar drug interactions - a phase IV clinical study of FDA data

Summary:

We study 41,660 people who take Naphcon-a (naphazoline hydrochloride; pheniramine maleate) and Lantus solostar (insulin glargine recombinant). There is no drug interaction reported.

The study analyzes what interactions people have when they take Naphcon-a and Lantus solostar. It is created by eHealthMe based on reports the from the FDA, and is updated regularly.

What is Naphcon-a?

Naphcon-a has active ingredients of naphazoline hydrochloride; pheniramine maleate. eHealthMe is studying from 21 Naphcon-a users. Check the latest studies of Naphcon-a.

What is Lantus solostar?

Lantus solostar has active ingredients of insulin glargine recombinant. It is often used in diabetes. eHealthMe is studying from 41,639 Lantus solostar users. Check the latest studies of Lantus solostar.

On Jul, 21, 2026

No report is found.

Do you take Naphcon-a and Lantus solostar?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

How the study uses the data?

The study uses data from the FDA. It is based on naphazoline hydrochloride; pheniramine maleate and insulin glargine recombinant (the active ingredients of Naphcon-a and Lantus solostar, respectively), and Naphcon-a and Lantus solostar (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.